Skip to main content
. Author manuscript; available in PMC: 2023 Apr 17.
Published in final edited form as: Cancer Res. 2022 Oct 17;82(20):3774–3784. doi: 10.1158/0008-5472.CAN-22-0970

Figure 7. Therapeutic implications of the melanoma cell intrinsic-Tim-3 signaling axis.

Figure 7.

The melanoma cell-Tim-3 receptor binds Galectin-9 and suppresses MAPK signaling to inhibit tumor growth (black, solid line). Ab-based melanoma-Tim-3 blockade (red, solid line) activates MAPK effectors, MEK and ERK, thereby unintentionally promoting tumorigenesis (red, dashed lines). Combination therapy with MEK inhibitors (MEKi) reverses Tim-3 Ab-mediated MEK activation (green, solid line), leading to desirable melanoma growth suppression (green, dashed line).